![Christine Siu](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Fortuna: - $ al 30/06/2026
La Sra. Christine E. Siu es Directora de Operaciones de BridgeBio Pharma, Inc. Forma parte del Consejo de Administración de Vividion Therapeutics, Inc. y Monte Rosa Therapeutics, Inc. Anteriormente, la Sra. Siu fue directora financiera y contable de Eidos Therapeutics, Inc., directora de negocios de The Bluefield Project to Cure Frontotemporal Dementia, directora senior de operaciones y desarrollo de negocios de Global Blood Therapeutics, Inc., directora de Third Rock Ventures LLC, vicepresidenta de Thomas, McNerney & Partners LLC, analista de Bear, Stearns & Co, Inc. y gestora de cartera de Warburg Pincus LLC. También formó parte del consejo de administración de NeuroTherapeutics Pharma, Inc. Se licenció en la Universidad de Michigan y obtuvo un MBA en la Harvard Business School.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
| 11/06/2026 | 0 ( -.--% ) | - $ | 30/06/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| MONTE ROSA THERAPEUTICS, INC. | Director/Miembro de la Junta | 01/12/2020 |
Vividion Therapeutics, Inc.
 Vividion Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biotechnology research company which develops precision therapeutics for cancers and immune disorders | Director/Miembro de la Junta | 04/05/2021 |
Bright Peak Therapeutics AG
 Bright Peak Therapeutics AG BiotechnologyHealth Technology Develops immuno-oncology therapeutics | Director/Miembro de la Junta | 10/06/2021 |
Bright Peak Therapeutics, Inc.
 Bright Peak Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops immunotherapies for the treatment of cancer and autoimmune diseases | Director/Miembro de la Junta | - |
| Empresas | Cargo | Fin |
|---|---|---|
| BRIDGEBIO PHARMA, INC. | Director de Operaciones | 23/07/2024 |
| EIDOS THERAPEUTICS, INC. | Director Financiero/CFO | 31/12/2019 |
The Bluefield Project to Cure Frontotemporal Dementia
 The Bluefield Project to Cure Frontotemporal Dementia The Bluefield Project to Cure Frontotemporal Dementia is a non-profit organization focused on accelerating the development of treatments and finding a cure for frontotemporal dementia (FTD), a fatal early-onset brain disease primarily affecting people under 60. The private company is based in San Francisco, CA. The organization targets FTD caused by mutations in the progranulin gene (GRN), funding basic, translational, and clinical research through a consortium of academic institutions and fostering collaboration between scientists and clinicians. Key therapeutic priorities include increasing progranulin levels, reducing neuroinflammation, and improving lysosomal function and protein homeostasis. Bluefield also supports biomarker studies and patient registries to aid research and clinical trial enrollment. The company was founded by Richards Donohoe Robin. | Corporate Officer/Principal | 01/01/2017 |
| GLOBAL BLOOD THERAPEUTICS, INC. | Director de Operaciones | 01/01/2014 |
Thomas, McNerney & Partners LLC
 Thomas, McNerney & Partners LLC Investment ManagersFinance TMT invests in companies located in the United States. The firm targets companies operating in the fields of life sciences and medical technology. It participates in restructuring transactions including spin-outs, roll ups and recapitalizations with an investment size of USD 5 - 40 million. | Analista de Capital Privado | 31/12/2010 |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 15 |
|---|---|
Bear, Stearns & Co., Inc.
 Bear, Stearns & Co., Inc. Investment Banks/BrokersFinance Provides investment banking, securities trading and brokerage Services | Finance |
Warburg Pincus LLC
 Warburg Pincus LLC Investment ManagersFinance Warburg Pincus invests in companies located across the globe. The firm focuses on a broad range of sectors and industries. It provides financing for buyout transactions. | Finance |
University of Michigan
 University of Michigan Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Thomas, McNerney & Partners LLC
Thomas, McNerney & Partners LLC Investment ManagersFinance TMT invests in companies located in the United States. The firm targets companies operating in the fields of life sciences and medical technology. It participates in restructuring transactions including spin-outs, roll ups and recapitalizations with an investment size of USD 5 - 40 million. | Finance |
Third Rock Ventures LLC
 Third Rock Ventures LLC Investment ManagersFinance Third Rock Ventures invests in companies located in the United States. The firm focuses on the healthcare. It participates in early stage capital requirements. The firm also acts as lead investor. | Finance |
NeuroTherapeutics Pharma, Inc.
 NeuroTherapeutics Pharma, Inc. Pharmaceuticals: MajorHealth Technology Develops biopharmaceutical and therapeutic drugs for central nervous system disorders | Health Technology |
Global Blood Therapeutics, Inc.
 Global Blood Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company which provides treatment and care of sickle cell disease for inherited blood disorder | Health Technology |
Harvard Business School
 Harvard Business School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The Bluefield Project to Cure Frontotemporal Dementia
The Bluefield Project to Cure Frontotemporal Dementia The Bluefield Project to Cure Frontotemporal Dementia is a non-profit organization focused on accelerating the development of treatments and finding a cure for frontotemporal dementia (FTD), a fatal early-onset brain disease primarily affecting people under 60. The private company is based in San Francisco, CA. The organization targets FTD caused by mutations in the progranulin gene (GRN), funding basic, translational, and clinical research through a consortium of academic institutions and fostering collaboration between scientists and clinicians. Key therapeutic priorities include increasing progranulin levels, reducing neuroinflammation, and improving lysosomal function and protein homeostasis. Bluefield also supports biomarker studies and patient registries to aid research and clinical trial enrollment. The company was founded by Richards Donohoe Robin. | |
Vividion Therapeutics, Inc.
Vividion Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biotechnology research company which develops precision therapeutics for cancers and immune disorders | Health Technology |
Eidos Therapeutics, Inc.
 Eidos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical stage biopharmaceutical company | Health Technology |
BridgeBio Pharma, Inc.
 BridgeBio Pharma, Inc. BiotechnologyHealth Technology Develops medicines for genetic diseases to patients | Health Technology |
Bright Peak Therapeutics AG
Bright Peak Therapeutics AG BiotechnologyHealth Technology Develops immuno-oncology therapeutics | Health Technology |
Monte Rosa Therapeutics, Inc.
 Monte Rosa Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biotechnology company that develops molecular glue degrader medicines for oncology, autoimmune and inflammatory diseases | Health Technology |
Bright Peak Therapeutics, Inc.
Bright Peak Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops immunotherapies for the treatment of cancer and autoimmune diseases | Health Technology |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.
